Black Friday Get Elite for just $149.00 Claim Now

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

By Oculis Holding AG | November 13, 2026, 4:05 PM

Oculis Holding AG

ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

Notification of managers' transaction - Anthony Rosenberg - 13 November 2026 RSU vest
Notification of managers' transaction - Christina Ackermann - 13 November 2026 RSU vest
Notification of managers' transaction - Arshad Khanani - 13 November 2026 RSU vest
Notification of managers' transaction - Robert Warner - 13 November 2026 RSU vest

Mentioned In This Article

Oculis Holding AG

Latest News

Nov-13	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Nov-09	Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline OCS GlobeNewswire
Nov-03	Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts OCS GlobeNewswire
Nov-02	Oculis Appoints Experienced Life Sciences Leader Bjorn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation OCS -6.66% GlobeNewswire
Oct-29	Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit OCS GlobeNewswire
Oct-22	Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis OCS GlobeNewswire
Oct-20	Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting OCS GlobeNewswire
Oct-19	Oculis lýkur slembiroðun i PREDICT-1 skraningarrannsokninni a Licaminlimab við TNFR1-miðluðum augnþurrki OCS GlobeNewswire
Oct-19	Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease OCS GlobeNewswire
Oct-08	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Oct-07	Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day OCS GlobeNewswire
Oct-01	Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS OCS -6.21% GlobeNewswire
Sep-30	Oculis Announces Resignation of Lionel Carnot from Board of Directors OCS GlobeNewswire
Sep-17	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Aug-24	First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis OCS GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)